RAPP – rapport therapeutics, inc. (US:NASDAQ)
Stock Stats
News
Rapport Therapeutics (RAPP) had its "buy" rating reaffirmed by BTIG Research. They now have a $53.00 price target on the stock.
Rapport Therapeutics Presents RAP-219 Focal Onset Seizure Phase 2a Follow-up Period Results Demonstrating Sustained Seizure Reduction at the 2026 American Academy of Neurology Annual Meeting
Rapport Therapeutics (RAPP) was upgraded by Raymond James Financial, Inc. to "strong-buy".
Rapport Therapeutics (RAPP) is now covered by Raymond James Financial, Inc.. They set a "strong-buy" rating and a $66.00 price target on the stock.
Rapport Therapeutics to Present New Phase 2 Treatment Follow-Up Data for RAP-219 in Focal Onset Seizures at the 2026 American Academy of Neurology Annual Meeting
Form ARS Rapport Therapeutics, For: Dec 31
Form DEFA14A Rapport Therapeutics,
Form DEF 14A Rapport Therapeutics, For: Jun 10
Form 4 Rapport Therapeutics, For: Apr 17 Filed by: TRV GP VI, LLC
Form 4 Rapport Therapeutics, For: Apr 17 Filed by: Yeleswaram Krishnaswamy
Top News Gainers
Top News Decliners
Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies
If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.